Natural Capsules Reports Q4FY26 Revenue Recovery, Full-Year Loss

Revenue from Operations (Q4FY26): ₹58.45 Cr
Profit After Tax (FY26): ₹(24.66) Cr

Reader Takeaway: Revenue growth driven by deferred orders masks ongoing annual losses; API business and PLI scheme are key for future recovery.

What just happened

Natural Capsules Limited (NCL) announced its financial results for the fourth quarter and full year ended March 31, 2026. The company reported a significant revenue recovery in Q4FY26, reaching ₹58.45 crore, a 55% increase from the previous quarter's ₹37.75 crore. This was attributed to the dispatch of deferred orders following an earlier shutdown at its Puducherry plant.

Despite the revenue rebound, NCL continued to report losses. The net loss for Q4FY26 narrowed to ₹4.98 crore from ₹7.12 crore in Q3FY26. However, the full financial year FY26 saw a consolidated net loss of ₹24.66 crore on revenues of ₹187.20 crore.

EBITDA for the quarter improved substantially to ₹1.33 crore from a negative ₹2.33 crore in the prior quarter, indicating better operational performance before interest, taxes, depreciation, and amortization.

Why this matters

The revenue recovery signals a return to normalcy after operational disruptions. However, the persistence of net losses, both quarterly and annually, remains a concern for shareholders. Investors will be watching the company's ability to achieve sustainable profitability and scale its newer ventures, particularly the API business.

The company's strategic focus on expanding its API business through its subsidiary, Natural Biogenex Private Limited, and leveraging the government's Production Linked Incentive (PLI) scheme for fermentation-based products are key initiatives for future growth.

The backstory

Natural Capsules Limited has faced operational challenges, including plant shutdowns, throughout FY26. The company is working to stabilize its core capsules business, aiming for optimal capacity utilization in FY27. The expansion into the API segment and contract manufacturing agreements signify a diversification strategy.

What changes now

With the commissioning of a new HPMC line and commercial sales commencing in the API segment, NCL anticipates contributing to revenue from the second half of FY27. The company also expects to benefit from approximately ₹67 crore in PLI incentives over six years, which could de-risk investments.

Risks to watch

A primary concern is the company's continued profitability, highlighted by the FY26 net loss. The API segment, while a growth area, currently has a lower margin profile and is subject to regulatory and customer clearances. Investors need to monitor if these factors can be overcome for improved financial health.

Peer comparison

(No direct peer comparison data provided in the filing.)

Context metrics (time-bound)

• Installed Capacity: Q4FY26 stood at 20.25 BCPA (Billion Capsules Per Annum).
• PLI Scheme Incentives: Expected ₹67 crore over 6 years.

What to track next

Investors should monitor the gradual scaling of the API business, the effective utilization of new capacity, and the realization of PLI scheme benefits. The company's ability to achieve positive net profit and improve margins will be crucial indicators.